View ValuationSepterna 将来の成長Future 基準チェック /06Septernaの収益と利益は、それぞれ年間2.7%と33.2%減少すると予測されています。EPS は年間28%で 減少すると予想されています。自己資本利益率は 3 年後に-19.9%になると予測されています。主要情報-33.2%収益成長率-28.00%EPS成長率Pharmaceuticals 収益成長14.8%収益成長率-2.7%将来の株主資本利益率-19.86%アナリストカバレッジGood最終更新日18 Jun 2026今後の成長に関する最新情報Major Estimate Revision • May 20Consensus revenue estimates increase by 13%The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from US$65.7m to US$74.1m. Forecast losses expected to reduce from -US$1.94 to -US$1.81 per share. Pharmaceuticals industry in the US expected to see average net income decline 13% next year. Consensus price target of US$44.25 unchanged from last update. Share price rose 13% to US$28.01 over the past week.分析記事 • May 14Earnings Update: Septerna, Inc. (NASDAQ:SEPN) Just Reported Its First-Quarter Results And Analysts Are Updating Their ForecastsAs you might know, Septerna, Inc. ( NASDAQ:SEPN ) just kicked off its latest quarterly results with some very strong...すべての更新を表示Recent updatesSeeking Alpha • Jun 17Septerna: A De-Risking GPCR Story With Near-Term Upside CatalystsSummary Septerna combines a strong balance sheet with multiple near-term clinical catalysts, supporting its premium valuation. SEPN is funded into mid-2029, reducing near-term dilution risk and enabling continued investment in its GPCR-focused pipeline. Key upcoming catalysts include SEP-631 Phase 2 progression for chronic urticaria and SEP-479 Phase 1 data for hypoparathyroidism. Current valuation is demanding, with upside dependent on successful clinical execution and de-risking of lead assets. Read the full article on Seeking AlphaRecent Insider Transactions Derivative • Jun 14Chief People Officer notifies of intention to sell stockSamira Shaikhly intends to sell 8k shares in the next 90 days after lodging an Intent To Sell Form on the 12th of June. If the sale is conducted around the recent share price of US$34.03, it would amount to US$287k. Since March 2026, Samira has owned 793.00 shares directly. Company insiders have collectively sold US$2.4m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions Derivative • May 27Chief People Officer notifies of intention to sell stockSamira Shaikhly intends to sell 12k shares in the next 90 days after lodging an Intent To Sell Form on the 26th of May. If the sale is conducted around the recent share price of US$28.36, it would amount to US$335k. Since March 2026, Samira has owned 793.00 shares directly. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months.分析記事 • May 21New Forecasts: Here's What Analysts Think The Future Holds For Septerna, Inc. (NASDAQ:SEPN)Septerna, Inc. ( NASDAQ:SEPN ) shareholders will have a reason to smile today, with the analysts making substantial...Major Estimate Revision • May 20Consensus revenue estimates increase by 13%The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from US$65.7m to US$74.1m. Forecast losses expected to reduce from -US$1.94 to -US$1.81 per share. Pharmaceuticals industry in the US expected to see average net income decline 13% next year. Consensus price target of US$44.25 unchanged from last update. Share price rose 13% to US$28.01 over the past week.分析記事 • May 14Earnings Update: Septerna, Inc. (NASDAQ:SEPN) Just Reported Its First-Quarter Results And Analysts Are Updating Their ForecastsAs you might know, Septerna, Inc. ( NASDAQ:SEPN ) just kicked off its latest quarterly results with some very strong...お知らせ • May 04Septerna, Inc., Annual General Meeting, Jun 26, 2026Septerna, Inc., Annual General Meeting, Jun 26, 2026.お知らせ • Apr 13Septerna, Inc. Announces Initiation of Phase 1 Trial for Oral PTH1R Agonist SEP-479 in HypoparathyroidismSepterna, Inc. announced the dosing of the first participants in its Phase 1 clinical trial of SEP-479, its potent oral small molecule PTH1R agonist being developed for the treatment of patients with hypoparathyroidism. The Phase 1 clinical trial is a single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of SEP-479 in healthy adult volunteers. The randomized, placebo-controlled Phase 1 clinical trial is expected to enroll up to 150 healthy adult participants. Dosing is underway in the SAD portion of the clinical trial, which will evaluate the safety and tolerability of SEP-479 at escalating oral doses. The MAD portion of the clinical trial is designed to evaluate the safety and tolerability of once-daily oral dosing of SEP-479 over multiple days of treatment, with secondary and exploratory endpoints including PK and PD, with the latter assessed by changes in endogenous PTH and serum calcium, as well as other biomarkers. Septerna anticipates reporting data from the trial in late 2026 or early 2027.お知らせ • Mar 11Septerna, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.Septerna, Inc. has filed a Follow-on Equity Offering in the amount of $150 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offeringお知らせ • Mar 02Septerna, Inc. Announces Positive Phase 1 Data for Sep-631, an Oral Mrgprx2 Nam for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development StrategySepterna, Inc. announced positive results from its Phase 1 clinical trial evaluating SEP-631, a potent and selective oral negative allosteric modulator (NAM) of Mas-related G protein-coupled receptor X2 (MRGPRX2). These findings are consistent with the insurmountable NAM mechanism of SEP-631 observed preclinically and support potent target engagement and functional blockade of MRGPRX2 signaling in humans, providing clinical proof-of-mechanism. Phase 2 Development Strategy: Septerna plans to initiate a Phase 2b clinical trial of SEP-631 in chronic spontaneous urticaria (CSU) in the second half of this year, following the completion of ongoing long-term toxicology studies. Following the CSU study initiation, the company also plans to pursue an open-label study in chronic inducible urticaria (CIndU), specifically in patients with symptomatic dermatographism. In a Phase 1 clinical trial, SEP-631 demonstrated favorable tolerability, once-daily pharmacokinetics and pharmacodynamic evidence of MRGPRX2 pathway inhibition.お知らせ • Jan 09Septerna, Inc. Appoints Mark A. Wilson as Chief Legal OfficerSepterna, Inc. has appointed Mark A. Wilson as Chief Legal Officer. Mr. Wilson is an accomplished pharmaceutical and biotech executive with more than 25 years of experience across intellectual property, corporate legal, strategic collaborations and corporate governance matters. Mr. Wilson joins Septerna from Nektar Therapeutics, where he most recently served as Senior Vice President and Chief Legal Officer. In this role, he served as chief attorney and senior manager for the legal, human resources, and information technology departments, and was a member of the company’s executive committee. During his tenure, Mr. Wilson served as lead attorney for several significant global development and commercialization collaborations, strategic corporate transactions and alternative financings, and he was responsible for the company’s global patent strategy. He joined Nektar in 2002 as Patent Counsel and held roles of increasing responsibility, including Vice President of Intellectual Property and General Counsel. Earlier in his career, Mr. Wilson was an associate at Reed & Associates, a patent law firm in Menlo Park, California, where he represented both start-up and Fortune 500 companies. Mr. Wilson holds a J.D. from Seton Hall University School of Law and a B.S. in Pharmacy from Rutgers University College of Pharmacy. He is registered to practice before the U.S. Patent and Trademark Office and is a member of the State Bar of California.分析記事 • Oct 05We're Not Worried About Septerna's (NASDAQ:SEPN) Cash BurnWe can readily understand why investors are attracted to unprofitable companies. For example, although...お知らせ • Sep 30Septerna Appoints Keith Gottesdiener to its Board of Directors and as Chairperson of R&D Committee of the BoardSepterna, Inc. announced the appointment of Keith Gottesdiener, M.D., to its board of directors. A seasoned biotechnology executive with over 30 years of experience advancing medicines from discovery through commercialization, Dr. Gottesdiener will serve as chairperson of a newly constituted R&D Committee of the Board. Dr. Gottesdiener has held leadership roles spanning academia, pharmaceutical R&D, and public biotechnology companies. He most recently served as President and Chief Executive Officer of Prime Medicine, Inc., leading the gene-editing company through IPO. Prior to that, Dr. Gottesdiener served as Chief Executive Officer of Rhythm Pharmaceuticals, Inc., where he oversaw the development and approval of setmelanotide for three indications in rare genetic forms of obesity. Before joining the biotechnology industry, Dr. Gottesdiener spent 16 years at Merck Research Laboratories, where he served as Worldwide Head of Late-Stage Development and Worldwide Head of Early Development, with major program responsibilities for the approval of more than 20 novel therapeutics and over 200 successful IND submissions. Earlier in his career, he was Associate Professor of Medicine at Columbia University College of Physicians and Surgeons. Dr. Gottesdiener previously served on the board of directors of Intercept Pharmaceuticals, Inc. He received his M.D. from the University of Pennsylvania Medical School and his A.B. in Applied Mathematics from Harvard University.お知らせ • Jun 30+ 4 more updatesSepterna, Inc.(NasdaqGM:SEPN) dropped from Russell 3000E Growth IndexSepterna, Inc.(NasdaqGM:SEPN) dropped from Russell 3000E Growth Indexお知らせ • Apr 30Septerna, Inc., Annual General Meeting, Jun 17, 2025Septerna, Inc., Annual General Meeting, Jun 17, 2025.分析記事 • Apr 28Companies Like Septerna (NASDAQ:SEPN) Are In A Position To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...お知らせ • Feb 19Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R AgonistSepterna, Inc. announced its decision to discontinue the Phase 1 single- and multiple-ascending dose (SAD/MAD) clinical trial of SEP-786 in healthy volunteers. SEP-786 is an oral small molecule agonist of the parathyroid hormone 1 receptor (PTH1R) being developed for the treatment of hypoparathyroidism. Septerna’s decision follows the observation of two unanticipated severe (Grade 3) events of elevated unconjugated bilirubin in the MAD portion of the Phase 1 trial, both of which were without elevations in ALT, AST, and GGT liver enzyme levels. Dosing was discontinued for both study participants, and the bilirubin elevations were reversible. Importantly, there were no events of liver injury, cholestasis, or hemolysis across all participants, and there were no serious adverse events (SAEs) in the Phase 1 trial. In completed 28-day preclinical toxicology studies, SEP-786 was generally well-tolerated, without predicted risk of bilirubin elevation. In response to these Phase 1 events, Septerna has initiated non-clinical studies to investigate the underlying mechanism behind the observed effect.Seeking Alpha • Feb 04Septerna: Great In Theory, Needs ProofSummary Septerna's Native Complex platform isolates GPCRs in their native form, enabling advanced drug discovery for previously undruggable targets, including oral small-molecule therapeutics. Lead molecule SEP-786 targets hypoparathyroidism, showing promising preclinical results and entering phase 1 trials, with data expected in mid-2025. SEPN has a $750mn market cap and $130mn in cash, providing a 6-7 quarter runway, but lacks clinical data until 2025. Despite the innovative platform, I recommend waiting for phase 1 data before investing due to the current lack of clinical proof. Read the full article on Seeking Alphaお知らせ • Jan 06Septerna, Inc Appoints Gil Labrucherie as Chief Financial OfficerSepterna, Inc. announced the appointment of Gil Labrucherie, CFA, J.D., as Chief Financial Officer. Mr. Labrucherie is a seasoned biopharma executive with more than 25 years of senior leadership experience in finance and legal roles for public biopharmaceutical and technology companies. Mr. Labrucherie most recently served as Chief Financial Officer and Chief Business Officer at ACELYRIN, where he led the company’s finance, accounting, investor relations and corporate communications, and business development organizations. Before that, he served as Chief Financial Officer and Chief Operating Officer of Nektar Therapeutics, where he led financial accounting and public reporting, business and strategic planning, corporate legal, intellectual property, government affairs, information technology and supply chain management, and previously served as Nektar’s Senior Vice President and General Counsel. Earlier in his career, Mr. Labrucherie held executive leadership positions at various high-growth technology companies, and he began his career as a corporate associate at Wilson Sonsini Goodrich & Rosati. Over the course of his career, Mr. Labrucherie has raised more than $1.5 billion in private and public equity capital and helped generate more than $1 billion in realized value from strategic partnering transactions. He currently serves on the board of Rezolute, Inc. Mr. Labrucherie holds a J.D. from the University of California Berkeley School of Law, a B.A. from the University of California Davis, and is a CFA charterholder and a member of the State Bar of California.お知らせ • Oct 26Septerna, Inc. has completed an IPO in the amount of $288 million.Septerna, Inc. has completed an IPO in the amount of $288 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 16,000,000 Price\Range: $18 Discount Per Security: $1.26 Transaction Features: Sponsor Backed Offering業績と収益の成長予測NasdaqGM:SEPN - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202858-155-151-174712/31/202766-121-126-1521012/31/202677-69-102-140103/31/202672-36107108N/A12/31/202546-49110110N/A9/30/202522-59103104N/A6/30/20251-88-83-81N/A3/31/20251-79-76-74N/A12/31/20241-72-70-67N/A9/30/20241-20-58-55N/A6/30/20241-10-51-48N/A3/31/20240-4-48-45N/A12/31/202301-42-39N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SEPN今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: SEPN今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: SEPN今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: SEPNの収益は今後 3 年間で減少すると予想されています (年間-2.7% )。高い収益成長: SEPNの収益は今後 3 年間で減少すると予測されています (年間-2.7% )。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SEPN 3 年以内に赤字になると予測されています。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/25 06:30終値2026/06/25 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Septerna, Inc. 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10 アナリスト機関Joshua SchimmerCantor Fitzgerald & Co.Seamus FernandezGuggenheim Securities, LLCRaghuram SelvarajuH.C. Wainwright & Co.7 その他のアナリストを表示
Major Estimate Revision • May 20Consensus revenue estimates increase by 13%The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from US$65.7m to US$74.1m. Forecast losses expected to reduce from -US$1.94 to -US$1.81 per share. Pharmaceuticals industry in the US expected to see average net income decline 13% next year. Consensus price target of US$44.25 unchanged from last update. Share price rose 13% to US$28.01 over the past week.
分析記事 • May 14Earnings Update: Septerna, Inc. (NASDAQ:SEPN) Just Reported Its First-Quarter Results And Analysts Are Updating Their ForecastsAs you might know, Septerna, Inc. ( NASDAQ:SEPN ) just kicked off its latest quarterly results with some very strong...
Seeking Alpha • Jun 17Septerna: A De-Risking GPCR Story With Near-Term Upside CatalystsSummary Septerna combines a strong balance sheet with multiple near-term clinical catalysts, supporting its premium valuation. SEPN is funded into mid-2029, reducing near-term dilution risk and enabling continued investment in its GPCR-focused pipeline. Key upcoming catalysts include SEP-631 Phase 2 progression for chronic urticaria and SEP-479 Phase 1 data for hypoparathyroidism. Current valuation is demanding, with upside dependent on successful clinical execution and de-risking of lead assets. Read the full article on Seeking Alpha
Recent Insider Transactions Derivative • Jun 14Chief People Officer notifies of intention to sell stockSamira Shaikhly intends to sell 8k shares in the next 90 days after lodging an Intent To Sell Form on the 12th of June. If the sale is conducted around the recent share price of US$34.03, it would amount to US$287k. Since March 2026, Samira has owned 793.00 shares directly. Company insiders have collectively sold US$2.4m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions Derivative • May 27Chief People Officer notifies of intention to sell stockSamira Shaikhly intends to sell 12k shares in the next 90 days after lodging an Intent To Sell Form on the 26th of May. If the sale is conducted around the recent share price of US$28.36, it would amount to US$335k. Since March 2026, Samira has owned 793.00 shares directly. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months.
分析記事 • May 21New Forecasts: Here's What Analysts Think The Future Holds For Septerna, Inc. (NASDAQ:SEPN)Septerna, Inc. ( NASDAQ:SEPN ) shareholders will have a reason to smile today, with the analysts making substantial...
Major Estimate Revision • May 20Consensus revenue estimates increase by 13%The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from US$65.7m to US$74.1m. Forecast losses expected to reduce from -US$1.94 to -US$1.81 per share. Pharmaceuticals industry in the US expected to see average net income decline 13% next year. Consensus price target of US$44.25 unchanged from last update. Share price rose 13% to US$28.01 over the past week.
分析記事 • May 14Earnings Update: Septerna, Inc. (NASDAQ:SEPN) Just Reported Its First-Quarter Results And Analysts Are Updating Their ForecastsAs you might know, Septerna, Inc. ( NASDAQ:SEPN ) just kicked off its latest quarterly results with some very strong...
お知らせ • May 04Septerna, Inc., Annual General Meeting, Jun 26, 2026Septerna, Inc., Annual General Meeting, Jun 26, 2026.
お知らせ • Apr 13Septerna, Inc. Announces Initiation of Phase 1 Trial for Oral PTH1R Agonist SEP-479 in HypoparathyroidismSepterna, Inc. announced the dosing of the first participants in its Phase 1 clinical trial of SEP-479, its potent oral small molecule PTH1R agonist being developed for the treatment of patients with hypoparathyroidism. The Phase 1 clinical trial is a single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of SEP-479 in healthy adult volunteers. The randomized, placebo-controlled Phase 1 clinical trial is expected to enroll up to 150 healthy adult participants. Dosing is underway in the SAD portion of the clinical trial, which will evaluate the safety and tolerability of SEP-479 at escalating oral doses. The MAD portion of the clinical trial is designed to evaluate the safety and tolerability of once-daily oral dosing of SEP-479 over multiple days of treatment, with secondary and exploratory endpoints including PK and PD, with the latter assessed by changes in endogenous PTH and serum calcium, as well as other biomarkers. Septerna anticipates reporting data from the trial in late 2026 or early 2027.
お知らせ • Mar 11Septerna, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.Septerna, Inc. has filed a Follow-on Equity Offering in the amount of $150 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
お知らせ • Mar 02Septerna, Inc. Announces Positive Phase 1 Data for Sep-631, an Oral Mrgprx2 Nam for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development StrategySepterna, Inc. announced positive results from its Phase 1 clinical trial evaluating SEP-631, a potent and selective oral negative allosteric modulator (NAM) of Mas-related G protein-coupled receptor X2 (MRGPRX2). These findings are consistent with the insurmountable NAM mechanism of SEP-631 observed preclinically and support potent target engagement and functional blockade of MRGPRX2 signaling in humans, providing clinical proof-of-mechanism. Phase 2 Development Strategy: Septerna plans to initiate a Phase 2b clinical trial of SEP-631 in chronic spontaneous urticaria (CSU) in the second half of this year, following the completion of ongoing long-term toxicology studies. Following the CSU study initiation, the company also plans to pursue an open-label study in chronic inducible urticaria (CIndU), specifically in patients with symptomatic dermatographism. In a Phase 1 clinical trial, SEP-631 demonstrated favorable tolerability, once-daily pharmacokinetics and pharmacodynamic evidence of MRGPRX2 pathway inhibition.
お知らせ • Jan 09Septerna, Inc. Appoints Mark A. Wilson as Chief Legal OfficerSepterna, Inc. has appointed Mark A. Wilson as Chief Legal Officer. Mr. Wilson is an accomplished pharmaceutical and biotech executive with more than 25 years of experience across intellectual property, corporate legal, strategic collaborations and corporate governance matters. Mr. Wilson joins Septerna from Nektar Therapeutics, where he most recently served as Senior Vice President and Chief Legal Officer. In this role, he served as chief attorney and senior manager for the legal, human resources, and information technology departments, and was a member of the company’s executive committee. During his tenure, Mr. Wilson served as lead attorney for several significant global development and commercialization collaborations, strategic corporate transactions and alternative financings, and he was responsible for the company’s global patent strategy. He joined Nektar in 2002 as Patent Counsel and held roles of increasing responsibility, including Vice President of Intellectual Property and General Counsel. Earlier in his career, Mr. Wilson was an associate at Reed & Associates, a patent law firm in Menlo Park, California, where he represented both start-up and Fortune 500 companies. Mr. Wilson holds a J.D. from Seton Hall University School of Law and a B.S. in Pharmacy from Rutgers University College of Pharmacy. He is registered to practice before the U.S. Patent and Trademark Office and is a member of the State Bar of California.
分析記事 • Oct 05We're Not Worried About Septerna's (NASDAQ:SEPN) Cash BurnWe can readily understand why investors are attracted to unprofitable companies. For example, although...
お知らせ • Sep 30Septerna Appoints Keith Gottesdiener to its Board of Directors and as Chairperson of R&D Committee of the BoardSepterna, Inc. announced the appointment of Keith Gottesdiener, M.D., to its board of directors. A seasoned biotechnology executive with over 30 years of experience advancing medicines from discovery through commercialization, Dr. Gottesdiener will serve as chairperson of a newly constituted R&D Committee of the Board. Dr. Gottesdiener has held leadership roles spanning academia, pharmaceutical R&D, and public biotechnology companies. He most recently served as President and Chief Executive Officer of Prime Medicine, Inc., leading the gene-editing company through IPO. Prior to that, Dr. Gottesdiener served as Chief Executive Officer of Rhythm Pharmaceuticals, Inc., where he oversaw the development and approval of setmelanotide for three indications in rare genetic forms of obesity. Before joining the biotechnology industry, Dr. Gottesdiener spent 16 years at Merck Research Laboratories, where he served as Worldwide Head of Late-Stage Development and Worldwide Head of Early Development, with major program responsibilities for the approval of more than 20 novel therapeutics and over 200 successful IND submissions. Earlier in his career, he was Associate Professor of Medicine at Columbia University College of Physicians and Surgeons. Dr. Gottesdiener previously served on the board of directors of Intercept Pharmaceuticals, Inc. He received his M.D. from the University of Pennsylvania Medical School and his A.B. in Applied Mathematics from Harvard University.
お知らせ • Jun 30+ 4 more updatesSepterna, Inc.(NasdaqGM:SEPN) dropped from Russell 3000E Growth IndexSepterna, Inc.(NasdaqGM:SEPN) dropped from Russell 3000E Growth Index
お知らせ • Apr 30Septerna, Inc., Annual General Meeting, Jun 17, 2025Septerna, Inc., Annual General Meeting, Jun 17, 2025.
分析記事 • Apr 28Companies Like Septerna (NASDAQ:SEPN) Are In A Position To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
お知らせ • Feb 19Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R AgonistSepterna, Inc. announced its decision to discontinue the Phase 1 single- and multiple-ascending dose (SAD/MAD) clinical trial of SEP-786 in healthy volunteers. SEP-786 is an oral small molecule agonist of the parathyroid hormone 1 receptor (PTH1R) being developed for the treatment of hypoparathyroidism. Septerna’s decision follows the observation of two unanticipated severe (Grade 3) events of elevated unconjugated bilirubin in the MAD portion of the Phase 1 trial, both of which were without elevations in ALT, AST, and GGT liver enzyme levels. Dosing was discontinued for both study participants, and the bilirubin elevations were reversible. Importantly, there were no events of liver injury, cholestasis, or hemolysis across all participants, and there were no serious adverse events (SAEs) in the Phase 1 trial. In completed 28-day preclinical toxicology studies, SEP-786 was generally well-tolerated, without predicted risk of bilirubin elevation. In response to these Phase 1 events, Septerna has initiated non-clinical studies to investigate the underlying mechanism behind the observed effect.
Seeking Alpha • Feb 04Septerna: Great In Theory, Needs ProofSummary Septerna's Native Complex platform isolates GPCRs in their native form, enabling advanced drug discovery for previously undruggable targets, including oral small-molecule therapeutics. Lead molecule SEP-786 targets hypoparathyroidism, showing promising preclinical results and entering phase 1 trials, with data expected in mid-2025. SEPN has a $750mn market cap and $130mn in cash, providing a 6-7 quarter runway, but lacks clinical data until 2025. Despite the innovative platform, I recommend waiting for phase 1 data before investing due to the current lack of clinical proof. Read the full article on Seeking Alpha
お知らせ • Jan 06Septerna, Inc Appoints Gil Labrucherie as Chief Financial OfficerSepterna, Inc. announced the appointment of Gil Labrucherie, CFA, J.D., as Chief Financial Officer. Mr. Labrucherie is a seasoned biopharma executive with more than 25 years of senior leadership experience in finance and legal roles for public biopharmaceutical and technology companies. Mr. Labrucherie most recently served as Chief Financial Officer and Chief Business Officer at ACELYRIN, where he led the company’s finance, accounting, investor relations and corporate communications, and business development organizations. Before that, he served as Chief Financial Officer and Chief Operating Officer of Nektar Therapeutics, where he led financial accounting and public reporting, business and strategic planning, corporate legal, intellectual property, government affairs, information technology and supply chain management, and previously served as Nektar’s Senior Vice President and General Counsel. Earlier in his career, Mr. Labrucherie held executive leadership positions at various high-growth technology companies, and he began his career as a corporate associate at Wilson Sonsini Goodrich & Rosati. Over the course of his career, Mr. Labrucherie has raised more than $1.5 billion in private and public equity capital and helped generate more than $1 billion in realized value from strategic partnering transactions. He currently serves on the board of Rezolute, Inc. Mr. Labrucherie holds a J.D. from the University of California Berkeley School of Law, a B.A. from the University of California Davis, and is a CFA charterholder and a member of the State Bar of California.
お知らせ • Oct 26Septerna, Inc. has completed an IPO in the amount of $288 million.Septerna, Inc. has completed an IPO in the amount of $288 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 16,000,000 Price\Range: $18 Discount Per Security: $1.26 Transaction Features: Sponsor Backed Offering